Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesJohnson & Johnson

Johnson & Johnson

Healthcare Drug Manufacturers - General
PortfolioPortfolio WatchlistWatchlist
Company price
266.16 USD -4.40 ( 1.63%)
Last update at 2026-11-03T20:59:00Z
VOLUME
4151797
Market Cap
643924.89M
P/E
30.96

Momentum Score

…

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
265.28
Low
271.07
High
52 Week Price Range
169.49
Low
281.07
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Johnson & Johnson is a diversified healthcare company focused on pharmaceuticals and medical devices after spinning off its consumer health unit, developing prescription medicines, device technologies and vaccines for global markets. Long-term growth may be supported by its drug pipeline, device innovation, global commercial scale and ability to deploy R&D and M&A to sustain cash flow. Investors may find the company attractive for its large market position, diversified revenue streams and history of consistent dividends.
Key risks include ongoing product-liability litigation, patent expirations and regulatory, pricing or reimbursement pressures that could reduce revenue and margins.

Risk Score
Low

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
270.56
Dividend Yield
1.97%
Revenue TTM
97929.00M
Revenue Per Share
40.67
Gross Profit TTM
66729.00M
Debt / Equity
0.59
ROE
25.74%
Net Debt
28224.00M
ROCE
23.13%
Diluted EPS TTM
8.63

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax 32581.00M 16687.00M 15062.00M 21725.00M 22776.00M
Net income 26804.00M 14066.00M 35153.00M 17941.00M 20878.00M
Selling general administrative 23676.00M 21969.00M 21012.00M 24765.00M 24659.00M
Selling and marketing expenses - - 500.00M - -
Gross profit 63937.00M 61350.00M 58413.00M 63854.00M 63920.00M
Reconciled depreciation 7503.00M 7339.00M 7486.00M 6970.00M 7390.00M
Ebit 33552.00M 17442.00M 21853.00M 17054.00M 18309.00M
Ebitda 41055.00M 24781.00M 29339.00M 24024.00M 25699.00M
Depreciation and amortization 7503.00M 7339.00M 7486.00M 6970.00M 7390.00M
Non operating income net other - - - -1381.00M -436.00M
Operating income 25596.00M 22149.00M 21853.00M 23917.00M 24417.00M
Other operating expenses 68597.00M 88821.00M 63299.00M 71240.00M 69228.00M
Interest expense 971.00M 755.00M 1247.00M 276.00M 183.00M
Tax provision 5777.00M 2621.00M 1736.00M 3784.00M 1898.00M
Interest income 1056.00M 1332.00M 1261.00M 490.00M 53.00M
Net interest income 85.00M 577.00M 489.00M 214.00M -130.00M
Extraordinary items -1000.00M 0.00M 21827.00M - -
Non recurring - - - 1104.00M 1152.00M
Income tax expense 5777.00M 2621.00M 1736.00M 3784.00M 1898.00M
Total revenue 94193.00M 88821.00M 85159.00M 94943.00M 93775.00M
Total operating expenses 38341.00M 66672.00M 36560.00M 40151.00M 39373.00M
Cost of revenue 30256.00M 27471.00M 26739.00M 31089.00M 29855.00M
Total other income expense net 6985.00M -6045.00M -6791.00M -2192.00M -1641.00M
Net income from continuing ops 26804.00M 14066.00M 13326.00M 17941.00M 20878.00M
Net income applicable to common shares 26804.00M 14066.00M 35153.00M 17941.00M 20878.00M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 199210.00M 180104.00M 167558.00M 187378.00M 182018.00M
Intangible assets 50403.00M 37618.00M 34175.00M 48325.00M 46392.00M
Other current assets 4153.00M - 4514.00M 3132.00M 3701.00M
Total liab 117666.00M 108614.00M 98784.00M 110574.00M 107995.00M
Total stockholder equity 81544.00M 71490.00M 68774.00M 76804.00M 74023.00M
Deferred long term liab - - - 6374.00M 7487.00M
Other current liab 33640.00M 30255.00M 30206.00M 31328.00M 30405.00M
Common stock 3120.00M 3120.00M 3120.00M 3120.00M 3120.00M
Capital stock 3120.00M 3120.00M 3120.00M 3120.00M 3120.00M
Retained earnings 168978.00M 155791.00M 153843.00M 128345.00M 123060.00M
Other liab - - - 26584.00M 31784.00M
Good will 48772.00M 44200.00M 36558.00M 45231.00M 35246.00M
Other assets 8.60M 20324.00M 17959.00M 17049.00M 17155.00M
Cash 19709.00M 24105.00M 21859.00M 14127.00M 14487.00M
Cash and equivalents 5993.00M 6123.00M 4814.00M 5368.00M 1901.00M
Total current liabilities 54126.00M 50321.00M 46282.00M 55802.00M 45226.00M
Current deferred revenue - - 2993.00M - -
Net debt 28224.00M 12529.00M 7473.00M 25532.00M 19264.00M
Short term debt 8495.00M 5983.00M 3451.00M 12771.00M 3766.00M
Short long term debt 8495.00M 5983.00M 3451.00M 12771.00M 3766.00M
Short long term debt total 47933.00M 36634.00M 29332.00M 39659.00M 33751.00M
Other stockholder equity -75624.00M -75680.00M -75662.00M -41694.00M -39099.00M
Property plant equipment 24469.00M 21618.00M 20898.00M 19803.00M 18962.00M
Total current assets 55624.00M 55893.00M 53495.00M 55294.00M 60979.00M
Net tangible assets - - - -16752.00M -13073.00M
Short term investments 393.00M 417.00M 1068.00M 9392.00M 17121.00M
Net receivables 17178.00M 18927.00M 14873.00M 16160.00M 15283.00M
Long term debt 39438.00M 30651.00M 25881.00M 26888.00M 29985.00M
Inventory 14191.00M 12444.00M 11181.00M 12483.00M 10387.00M
Accounts payable 11991.00M 10311.00M 9632.00M 11703.00M 11055.00M
Noncontrolling interest in consolidated entity - - 0.00M - -
Accumulated other comprehensive income -14930.00M -11741.00M -12527.00M -12967.00M -13058.00M
Additional paid in capital - - 0.00M - -
Common stock total equity - - - 3120.00M 3120.00M
Retained earnings total equity - - - 128345.00M 123060.00M
Treasury stock - - -75662.00M -41694.00M -39099.00M
Non currrent assets other 14368.00M 11414.00M 14153.00M 9602.00M 10216.00M
Non current assets total 143586.00M 124211.00M 114063.00M 132084.00M 121039.00M
Long term debt total 39438.00M 30651.00M 25881.00M 26888.00M 29985.00M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 741.00M -18599.00M 878.00M 9225.00M -5388.00M
Change to liabilities - - - -881.00M 1376.00M
Total cashflows from investing activities -23588.00M -18599.00M 878.00M -12371.00M -8683.00M
Net borrowings 9637.00M 10051.00M -2734.00M 7452.00M -990.00M
Total cash from financing activities -5539.00M -3132.00M -15825.00M -8871.00M -14047.00M
Change to operating activities - - - -1292.00M -3025.00M
Net income 26804.00M 14066.00M 35153.00M 17941.00M 20878.00M
Change in cash -4396.00M 2246.00M 7732.00M -360.00M 502.00M
Begin period cash flow 24105.00M 21859.00M 14127.00M 14487.00M 13985.00M
End period cash flow 19709.00M 24105.00M 21859.00M 14127.00M 14487.00M
Total cash from operating activities 24530.00M 24266.00M 22791.00M 21194.00M 23410.00M
Issuance of capital stock 0.00M 0.00M 4241.00M - -
Depreciation 7503.00M 7339.00M 7486.00M 6970.00M 7390.00M
Other cashflows from investing activities -1956.00M 235.00M -3063.00M -17587.00M 357.00M
Dividends paid 12381.00M 11823.00M 11770.00M -11682.00M -11032.00M
Change to inventory -1450.00M -1128.00M -1323.00M -2527.00M -1248.00M
Change to account receivables -1781.00M -406.00M -624.00M -1290.00M -2402.00M
Sale purchase of stock -5953.00M -2432.00M -5054.00M -6035.00M -3456.00M
Other cashflows from financing activities 3158.00M 1072.00M -508.00M 17530.00M 395.00M
Change to netincome - - - 294.00M -620.00M
Capital expenditures 4832.00M 4424.00M 4543.00M 4009.00M 3652.00M
Change receivables - - - -1290.00M -2402.00M
Cash flows other operating - - - 687.00M -1964.00M
Cash and cash equivalents changes - - - -48.00M 680.00M
Change in working capital -12718.00M 1837.00M 2507.00M -4011.00M -4238.00M
Stock based compensation 1354.00M 1176.00M 1162.00M 1138.00M 1135.00M
Other non cash items 49.00M 2031.00M 2504.00M 819.00M 324.00M
Free cash flow 19698.00M 19842.00M 18248.00M 17185.00M 19758.00M

Peer Comparison*

Sector: Healthcare Industry: Drug Manufacturers - General

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
JNJ
Johnson & Johnson		 -4.40
1.63%		 266.16 30.96 20.79 6.58 7.55 6.84 19.73
LLY
Eli Lilly and Company		 -1.60
0.11%		 1409.39 38.16 24.15 12.72 29.95 13.31 25.43
ABBV
AbbVie Inc		 -2.84
0.98%		 286.00 74.10 16.21 7.22 50.46 8.18 27.04
RHHVF
Roche Holding AG Participation		 -10.00
2.06%		 475.00 24.16 16.53 5.71 8.88 4.94 14.76
RHHBY
Roche Holding Ltd ADR		 -1.51
2.49%		 59.17 23.48 16.31 5.56 8.78 4.94 14.76

Profile*

Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.

One Johnson & Johnson Plaza, New Brunswick, NJ, United States, 08933

732 524 0400

https://www.jnj.com

138200

Name Title Year Born
Mr. Alex Gorsky Exec. Chairman 1960
Mr. Joaquin Duato CEO & Director 1963
Mr. Joseph J. Wolk CPA Exec. VP & CFO 1967
Ms. Jennifer L. Taubert Exec. VP & Worldwide Chairman of Pharmaceuticals 1964
Mr. Robert J. Decker Jr. Controller & Chief Accounting Officer 1972
Mr. James Swanson Exec. VP & Chief Information Officer NA
Ms. Jessica Moore VP of Investor Relations NA
Mr. Dirk Brinckman Chief Compliance Officer NA
Ms. Elizabeth Forminard Exec. VP & Gen. Counsel NA
Dr. Peter M. Fasolo Ph.D. Exec. VP & Chief HR Officer 1963

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

VNP
CAD 32.54
+24.44%
HUT
CAD 88.32
+14.81%
KEEL
CAD 3.05
+14.66%
MTY
CAD 36.63
+13.58%
CNL
CAD 15.98
+11.90%
MOON
CAD 4.72
-12.34%
EU
CAD 0.96
-8.57%
URE
CAD 1.02
-8.48%
AP-UN
CAD 3.71
-8.17%
HG
CAD 3.77
-8.05%

Equity Sectors*

  • Basic Materials

    -1.14%

  • Communication Services

    +0.65%

  • Consumer Cyclical

    +0.09%

  • Consumer Defensive

    -0.57%

  • Energy

    -0.15%

  • Financial Services

    +0.08%

  • Healthcare

    +2.18%

  • Industrials

    +2.04%

  • Real Estate

    -0.25%

  • Technology

    +1.02%

  • Utilities

    +0.66%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…